DNA methylation of sarcosine dehydrogenase (SARDH) loci as a prognosticator for renal cell carcinoma

  • Authors:
    • Mehrdad Mazdak
    • Hossein Tezval
    • Janne Carmen Callauch
    • Natalia Dubrowinskaja
    • Inga Peters
    • Carsten Bokemeyer
    • Jörg Hennenlotter
    • Arnulf Stenzl
    • Markus A. Kuczyk
    • Jürgen Serth
  • View Affiliations

  • Published online on: September 9, 2019     https://doi.org/10.3892/or.2019.7305
  • Pages: 2159-2168
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

DNA methylation plays an important role in the genesis and progression of tumor diseases. To identify new DNA methylation markers possibly associated with the clinical characteristics of renal cell carcinoma (RCC), we investigated loci in the sarcosine dehydrogenase (SARDH) gene. SARDH is involved in the metabolism of the glycine‑derivative sarcosine and is closely linked through a functional control loop. Statistical evaluation of methylation data and clinical characteristics of patients showed that kidney tumors with clinically aggressive features such as a high tumor stage, positive lymph nodes, distant metastases or a previously advanced tumor status exhibited significantly lower methylation of a locus in the SARDH gene. Moreover, SARDH methylation was found to be a significant prognostic factor for recurrence‑free survival in RCC patients showing statistical independence from the clinical prognosticators, grade, stage and state of metastasis. In conclusion, the methylation status of the SARDH‑CGI was identified as an independent prognostic candidate marker for RCC.

References

1 

Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Perez JR, Agarwal N and Vogelzang NJ: Real-world survival outcomes and prognostic factors among patients receiving first targeted therapy for advanced renal cell carcinoma: A SEER-medicare database analysis. Clin Genitourin Cancer. 15:e573–e582. 2017. View Article : Google Scholar : PubMed/NCBI

2 

Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI

3 

Issa JP: CpG island methylator phenotype in cancer. Nat Rev Cancer. 4:988–993. 2004. View Article : Google Scholar : PubMed/NCBI

4 

Lasseigne BN and Brooks JD: The role of DNA methylation in renal cell carcinoma. Mol Diagn Ther. 22:431–442. 2018. View Article : Google Scholar : PubMed/NCBI

5 

Mendoza-Pérez J, Gu J, Herrera LA, Tannir NM, Matin SF, Karam JA, Huang M, Chang DW, Wood CG and Wu X: Genomic DNA hypomethylation and risk of renal cell carcinoma: A case-control study. Clin Cancer Res. 22:2074–2082. 2016. View Article : Google Scholar : PubMed/NCBI

6 

Cancer Genome Atlas Research Network, . Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 499:43–49. 2013. View Article : Google Scholar : PubMed/NCBI

7 

Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR and Linehan WM: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA. 91:9700–9704. 1994. View Article : Google Scholar : PubMed/NCBI

8 

Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, et al: The Cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 23:313–326 e5. 2018. View Article : Google Scholar : PubMed/NCBI

9 

Battagli C, Uzzo RG, Dulaimi E, Ibanez de Caceres I, Krassenstein R, Al-Saleem T, Greenberg RE and Cairns P: Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res. 63:8695–8699. 2003.PubMed/NCBI

10 

Slater AA, Alokail M, Gentle D, Yao M, Kovacs G, Maher ER and Latif F: DNA methylation profiling distinguishes histological subtypes of renal cell carcinoma. Epigenetics. 8:252–267. 2013. View Article : Google Scholar : PubMed/NCBI

11 

Malouf GG, Su X, Zhang J, Creighton CJ, Ho TH, Lu Y, Raynal NJ, Karam JA, Tamboli P, Allanick F, et al: DNA methylation signature reveals cell ontogeny of renal cell carcinomas. Clin Cancer Res. 22:6236–6246. 2016. View Article : Google Scholar : PubMed/NCBI

12 

Morris MR, Ricketts CJ, Gentle D, McRonald F, Carli N, Khalili H, Brown M, Kishida T, Yao M, Banks RE, et al: Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene. 30:1390–1401. 2011. View Article : Google Scholar : PubMed/NCBI

13 

Klatte T, Rossi SH and Stewart GD: Prognostic factors and prognostic models for renal cell carcinoma: A literature review. World J Urol. 36:1943–1952. 2018. View Article : Google Scholar : PubMed/NCBI

14 

Choueiri TK, Fay AP, Gagnon R, Lin Y, Bahamon B, Brown V, Rosenberg JE, Hutson TE, Baker-Neblett KL, Carpenter C, et al: The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin Cancer Res. 19:5218–5226. 2013. View Article : Google Scholar : PubMed/NCBI

15 

Stewart GD, O'Mahony FC, Laird A, Eory L, Lubbock AL, Mackay A, Nanda J, O'Donnell M, Mullen P, McNeill SA, et al: Sunitinib treatment exacerbates intratumoral heterogeneity in metastatic renal cancer. Clin Cancer Res. 21:4212–4223. 2015. View Article : Google Scholar : PubMed/NCBI

16 

Peters I, Dubrowinskaja N, Abbas M, Seidel C, Kogosov M, Scherer R, Gebauer K, Merseburger AS, Kuczyk MA, Grünwald V and Serth J: DNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies. PLoS One. 9:e914402014. View Article : Google Scholar : PubMed/NCBI

17 

Dubrowinskaja N, Gebauer K, Peters I, Hennenlotter J, Abbas M, Scherer R, Tezval H, Merseburger AS, Stenzl A, Grünwald V, et al: Neurofilament Heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response. Cancer Med. 3:300–309. 2014. View Article : Google Scholar : PubMed/NCBI

18 

Hu J, Jin L, Li Y, He T, Liu J, Shi B, Yang S, Gui Y, Mao X, Lai Y and Ni L: Multilocular cystic renal cell carcinoma: A case report and review of the literature. Mol Clin Oncol. 8:326–329. 2018.PubMed/NCBI

19 

Kubiak-Wlekly A and Niemir ZI: Neprilysin-structure of the gene and protein product and the localization of expression. Pol Merkur Lekarski. 27:48–50. 2009.(In Polish). PubMed/NCBI

20 

van Vlodrop IJ, Niessen HE, Derks S, Baldewijns MM, van Criekinge W, Herman JG and van Engeland M: Analysis of promoter CpG island hypermethylation in cancer: Location, location, location! Clin Cancer Res. 17:4225–4231. 2011. View Article : Google Scholar : PubMed/NCBI

21 

Morris MR, Ricketts C, Gentle D, Abdulrahman M, Clarke N, Brown M, Kishida T, Yao M, Latif F and Maher ER: Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene. 29:2104–2117. 2010. View Article : Google Scholar : PubMed/NCBI

22 

Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, et al: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 457:910–914. 2009. View Article : Google Scholar : PubMed/NCBI

23 

Martínez-Chantar ML, Vázquez-Chantada M, Ariz U, Martínez N, Varela M, Luka Z, Capdevila A, Rodríguez J, Aransay AM, Matthiesen R, et al: Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology. 47:1191–1199. 2008. View Article : Google Scholar : PubMed/NCBI

24 

Chen YM, Shiu JY, Tzeng SJ, Shih LS, Chen YJ, Lui WY and Chen PH: Characterization of glycine-N-methyltransferase-gene expression in human hepatocellular carcinoma. Int J Cancer. 75:787–793. 1998. View Article : Google Scholar : PubMed/NCBI

25 

Lim SO, Park SJ, Kim W, Park SG, Kim HJ, Kim YI, Sohn TS, Noh JH and Jung G: Proteome analysis of hepatocellular carcinoma. Biochem Biophys Res Commun. 291:1031–1037. 2002. View Article : Google Scholar : PubMed/NCBI

26 

Waalkes S, Atschekzei F, Kramer MW, Hennenlotter J, Vetter G, Becker JU, Stenzl A, Merseburger AS, Schrader AJ, Kuczyk MA and Serth J: Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer. BMC Cancer. 10:5032010. View Article : Google Scholar : PubMed/NCBI

27 

Gebauer K, Peters I, Dubrowinskaja N, Hennenlotter J, Abbas M, Scherer R, Tezval H, Merseburger AS, Stenzl A, Kuczyk MA and Serth J: Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma. Br J Cancer. 108:131–138. 2013. View Article : Google Scholar : PubMed/NCBI

28 

Eschenbrenner M and Jorns MS: Cloning and mapping of the cDNA for human sarcosine dehydrogenase, a flavoenzyme defective in patients with sarcosinemia. Genomics. 59:300–308. 1999. View Article : Google Scholar : PubMed/NCBI

29 

Colella S, Shen L, Baggerly KA, Issa JP and Krahe R: Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques. 35:146–150. 2003. View Article : Google Scholar : PubMed/NCBI

30 

Tezval H, Dubrowinskaja N, Peters I, Reese C, Serth K, Atschekzei F, Hennenlotter J, Stenzl A, Kuczyk MA and Serth J: Tumor specific epigenetic silencing of corticotropin releasing hormone -binding protein in renal cell carcinoma: Association of hypermethylation and metastasis. PLoS One. 11:e01638732016. View Article : Google Scholar : PubMed/NCBI

31 

Heger Z, Merlos Rodrigo MA, Michalek P, Polanska H, Masarik M, Vit V, Plevova M, Pacik D, Eckschlager T, Stiborova M and Adam V: Sarcosine up-regulates expression of genes involved in cell cycle progression of metastatic models of prostate cancer. PLoS One. 11:e01658302016. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

November 2019
Volume 42 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Mazdak, M., Tezval, H., Callauch, J.C., Dubrowinskaja, N., Peters, I., Bokemeyer, C. ... Serth, J. (2019). DNA methylation of sarcosine dehydrogenase (SARDH) loci as a prognosticator for renal cell carcinoma. Oncology Reports, 42, 2159-2168. https://doi.org/10.3892/or.2019.7305
MLA
Mazdak, M., Tezval, H., Callauch, J. C., Dubrowinskaja, N., Peters, I., Bokemeyer, C., Hennenlotter, J., Stenzl, A., Kuczyk, M. A., Serth, J."DNA methylation of sarcosine dehydrogenase (SARDH) loci as a prognosticator for renal cell carcinoma". Oncology Reports 42.5 (2019): 2159-2168.
Chicago
Mazdak, M., Tezval, H., Callauch, J. C., Dubrowinskaja, N., Peters, I., Bokemeyer, C., Hennenlotter, J., Stenzl, A., Kuczyk, M. A., Serth, J."DNA methylation of sarcosine dehydrogenase (SARDH) loci as a prognosticator for renal cell carcinoma". Oncology Reports 42, no. 5 (2019): 2159-2168. https://doi.org/10.3892/or.2019.7305